Kymera Therapeutics, Inc.

Equities

KYMR

US5015751044

Market Closed - Nasdaq Other stock markets 21:00:00 08/05/2026 BST			5-day change	1st Jan Change
86.08 ^USD	+1.71%		+6.65%	+10.63%

05-06	Canaccord Genuity Initiates Kymera Therapeutics at Buy With $106 Price Target	MT
05-05	Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, A First-In-Class, Oral Irf5 Degrader, At Digestive Disease Week	CI

Transcript : Kymera Therapeutics, Inc., Q4 2025 Earnings Call, Feb 26, 2026

Published on 02/26/2026 at 08:06 pm GMT - Modified on 03/16/2026 at 12:57 pm GMT

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good day, everyone. My name is Kahai Illani, and I will be your conference operator today. At this time, I would like to welcome you to the Kymera

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Kymera Therapeutics, Inc.

05-06	Canaccord Genuity Initiates Kymera Therapeutics at Buy With $106 Price Target	MT
05-05	Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, A First-In-Class, Oral Irf5 Degrader, At Digestive Disease Week	CI
04-30	Kymera Therapeutics, Inc., Q1 2026 Earnings Call, Apr 30, 2026
04-30	Kymera Therapeutics Shares Fall After Q1 Loss Narrows, Collaboration Revenue Rises	MT
04-30	Kymera Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-30	Earnings Flash (KYMR) Kymera Therapeutics Posts Q1 Net Loss $0.71 a Share, vs. FactSet Est of $0.88 Loss	MT
04-30	Earnings Flash (KYMR) Kymera Therapeutics, Inc. Reports Q1 Revenue $34.4M, vs. FactSet Est of $8.3M	MT
04-13	Kymera Therapeutics Wins FDA Fast Track for Oral Asthma Drug	MT
04-13	Kymera Therapeutics, Inc. Announces U.S. FDA Fast Track Designation for KT-621, A First-In-Class, Oral Stat6 Degrader for the Treatment of Moderate to Severe Asthma	CI
04-09	Kymera to Receive $45 Million Milestone Payment as Gilead Exercises Option to License KT-200	MT
04-09	Kymera Therapeutics announces Gilead Sciences' option exercise to license KT-200, oral CDK2 molecular glue degrader development candidate	RE
04-09	Kymera Therapeutics and Gilead Sciences Enter License Agreement for Kt-200 with $45 Million Milestone Payment	CI
03-28	Kymera Therapeutics Presents KT-621 BroADen Data In Late-Breaking Research Session At The American Academy Of Dermatology Annual Meeting	CI
03-12	Kymera Therapeutics, Inc. Presents at Barclays 28th Annual Global Healthcare Conference, Mar-12-2026 09:30 AM
03-03	UBS Adjusts Price Target on Kymera Therapeutics to $128 From $90, Maintains Buy Rating	MT